Skip to Main Content

Twist Bioscience Corporation (NASDAQ: TWST) Securities Fraud Class Action

View Complaint
COMPANY         Twist Bioscience Corporation 
COURT United States District Court for the Northern District of California
CASE NUMBER 22-cv-08168
JUDGE The Hon. Edward John Davila
CLASS PERIOD December 13, 2019, and November 14, 2022
SECURITY TYPE  Common Stock

Case Background:

This is a class action lawsuit  on behalf of those who purchased or acquired Twist Bioscience Corporation ("Twist") (NASDAQ: TWST) common stock between December 13, 2019 and November 14, 2022, both dates inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about Twist’s business and operations.  Specifically, as alleged in the Scorpion Report, Defendants overstated the commercial viability of Twist’s synthetic DNA manufacturing technology while engaging in accounting fraud and using unsustainable pricing to inflate the company’s true financial condition and prospects.

Current Status of Case:

On December 6, 2023, Defendants filed a Motion to Dismiss which has been fully briefed by the parties and is pending the Court’s decision.  This action is ongoing

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.